

Press Release

Miromatrix Medical Adds Paul Buckman, John Erb and Mark Wagner to Its Board of Directors

Wednesday April 19, 2017 8:00am ET

MINNEAPOLIS, MN – April 19, 2017 – Miromatrix Medical Inc., today announced the appointment of Paul Buckman, John Erb and Mark Wagner to the Board of Directors effective immediately. Collectively they bring over a 100 years of leadership experience in the medical device industry to Miromatrix. In addition, the Company announced that Walter Sembrowich, Ph.D. and Tim Pawlenty, following 7 and 6 years of service respectively, resigned effective immediately to help transition the composition of the Board. Effective with these membership changes, the Board of Directors will now consist of six members.

Mr. Buckman brings over 35 years of medical device and leadership experience. Most recently CEO of Conventus Orthopaedics and had previously held CEO roles at SentreHEART, Inc, Pathway Medical Technologies (acquired by Bayer) and Devax, Inc. (acquired by Biosensors). He was also co-founder and CEO of ev3 which was acquired by Covidien. He currently is a Board member for Xtant Medical, Ablative Solutions Inc., Aortica, Coventus Orthopaedics, Caisson Interventional, NeuroOne and BioStar Ventures. Mr. Buckman brings a broad range of leadership, medical device and commercialization experience to Miromatrix.

Mr. Erb brings over 40 years of medical device and leadership experience. He is currently CEO of Sunshine Heart and NuAx Inc. and Chairman of the Board for Osprey Medical Inc. He has previously held CEO roles at CHF Solutions (acquired by Gambro) and IntraTherapeutics, Inc. (acquired by Sulzer Medica). He was co-founder of NuAx and was Chairman of the Board for Vascular Solutions which was just acquired by Teleflex in 2017. In addition, he served on the Boards of SenoRx, Inc. (acquired by CR Bard) and CryoCath Technologies (acquired by Medtronic). Mr. Erb brings a broad range of leadership, medical device and commercialization experience to Miromatrix.

Mr. Wagner brings over 35 years of medical device and leadership experience. He has previously held CEO roles at Celleration Inc. (acquired by Alliqua), ReShape Medical, ProVation Medical (acquired by Wolters Kluwer) and Survivalink (acquired by Cardiac Science Inc.). He also co-founded Orasi Medical. He currently is Chairman of the Board for Preceptis, Executive Chair for Zipnosis and a Board member for Minnetronix and Alliqua BioMedical. Mr. Wagner brings a broad range of leadership and direct wound care experience to Miromatrix.

“I am pleased to add these three experienced medical device professionals to our Board of Directors,” commented Jeff Ross, Ph.D., Chief Executive Officer of Miromatrix Medical Inc. “Mr. Buckman, Mr. Erb and Mr. Wagner, individually would be a powerful addition for Miromatrix and collectively, this is a major achievement. It demonstrates the potential of Miromatrix’ technology, our people and our mission. I am personally looking forward to working closely with the new Board members as we continue to execute on our commercialization plans and development of transplantable organs. We also want to thank Dr. Sembrowich and Mr. Pawlenty who have seen us grow from a few employees with just a vision to where we are today leading the world in bioengineering a whole liver and having two commercial products,” Dr. Ross added.

About Miromatrix

Miromatrix Medical Inc., is a biotechnology company engaged in the development of fully biological human organs to solve the chronic shortage of transplantable organs, utilizing its patented perfusion decellularization/recellularization technology, as well as organ-derived biological products such as MIROMESH® and MIRODERM® for soft tissue reinforcement and advanced wound care. Miromatrix’ perfusion decellularization/recellularization technology is protected by a series of issued patents and pending patent applications in all major markets around the world. In addition to MIROMESH and MIRODERM, internal development programs at Miromatrix focus primarily on creating fully implantable human organs including

livers, kidneys and heart products, with collaborators including The Mayo Clinic, Texas Heart Institute and Mount Sinai Hospital, and aim at eliminating the organ transplant waiting list.

Contact:

Jeff Ross, Ph.D.

(952) 942-6000

jross@miromatrix.com

April 19, 2017